Skip to main
SVRA

Savara (SVRA) Stock Forecast & Price Target

Savara (SVRA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Savara Inc. has shown considerable improvements in Health-related Quality of Life (HrQoL) and exercise capacity across various disease-severity subgroups, demonstrating the efficacy of its main product candidate, molgramostim, in treating autoimmune pulmonary alveolar proteinosis (aPAP). The company's substantial progress in Phase 3 development, along with a de-risked Chemistry, Manufacturing, and Controls (CMC) strategy, positions it favorably for the acceptance of its Biologics License Application (BLA) and enhances the likelihood of a successful Pre-Approval Inspection. Furthermore, the company's increased probability of success to 85% boosts investor confidence, while broader adoption of diagnostic pathways enhances its launch preparedness for molgramostim.

Bears say

Savara Inc faces significant risks regarding its investment potential, primarily stemming from potential failure to secure regulatory approval for its main product candidate, molgramostim, which is currently in Phase 3 development. Additionally, the company may experience a smaller-than-anticipated commercial opportunity due to the limited market size of autoimmune pulmonary alveolar proteinosis (aPAP), competitive dynamics, and pricing pressures. The recent decision to resubmit the Biologics License Application (BLA) following a Refusal to File (RTF) letter raises concerns about the reliability of the chemistry, manufacturing, and controls (CMC) package, further complicating the company’s path to approval and market entry.

Savara (SVRA) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Savara (SVRA) Forecast

Analysts have given Savara (SVRA) a Buy based on their latest research and market trends.

According to 7 analysts, Savara (SVRA) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Savara (SVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.